A DNA Vaccine to Protect against Ebola and Marburg Filoviruses Could Gain Fast-track Approval
Inovio Pharmaceuticals (NYSE MKT: INO) is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal protection against known, as well as new unmatched strains of pathogens such as influenza.
Last week, it was announced that that in a preclinical study of Inovio's SynCon® DNA vaccine against Ebola and Marburg filoviruses, labeled "Category A" bioterrorism agents by the U.S. government, the vaccine induced strong and broad immune responses and demonstrated 100% protection against death following a challenge with multiple variants of the pathogen in two animal models.
There is no approved vaccine or therapy available against these highly virulent pathogens that have killed up to 90% of the people they infected. This is exactly why it would make sense to speed up the approval process for a vaccine should it prove to be safe and effective.
Last month, Inovio Pharmaceuticals was recognized with “Best Therapeutic Vaccine” and “Best Early Stage Biotech” awards at World Vaccine Congress 2013. Inovio also announced that its universal H1N1 influenza vaccine achieved protective immune responses comparable to conventional vaccine in Phase 1 study.
Today before the market open, The Green Baron Report introduced coverage of Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) and its new alert can be viewed on its website at www.TheGreenBaron.com. The report states “INO appears pegged to continue its recent rally and we view this as both a nice trading situation, as well as a great long-term investment supported by solid fundamentals.” The report notes that INO carries a Zacks Rank of #1 (Strong Buy). See Green Baron disclaimer: http://www.thegreenbaron.com/Disclaimer.htm.
Editors Note: Phil Kreider and Matt Chipman represent TheGreenBaron.com home of the best FREE stock picks on Wall Street and the world famous Green Baron Report. Joining is fast, easy and absolutely free. Stocks featured by The Green Baron often see gains of 100% or more! To subscribe to The Green Baron Report visit www.TheGreenBaron.com and to sign up for The Green Baron’s FREE Stock Text Alerts - text “JOIN” at 561-284-3259
